Stemina to Present Sponsored Session, Poster at SOT’s Annual Meeting & ToxExpo 2017
Feb 20, 2017Stemina Biomarker Discovery will be well represented at the Society of Toxicology’s 56th Annual Meeting and ToxExpo. In addition to participating in SOT as an exhibitor (booth 2506), Stemina’s Jessica Palmer, Associate Director of Toxicology, will present new research in two sessions: Poster session: Monday, March 13th | 9:30 AM – 12:45 PM | P331
NeuroPointDX Partners with Ovid Therapeutics to Identify Biomarkers for Angelman Syndrome
Feb 9, 2017Together, Ovid and NeuroPointDX will use metabolomics data to better understand the rare neuro-genetic disorder known as Angelman Syndrome. NeuroPointDX’s metabolomics technology will be used in Ovid’s phase 2 STARS trial of its drug candidate, OV101. Read more
Stemina Hosts Webinar: Exposure-Based Developmental Toxicity Prediction with the devTOX quickPredict Assay
Jan 18, 2017The required in vivo preclinical models for developmental toxicity testing have varying degrees of concordance with human effects, having approximately 70% concordance to known human developmental toxins. Development and validation of alternative methods for assessing developmental toxicity potential, such as the devTOX quickPredict assay (devTOXqP) would decrease the time, expense, and use of vertebrate animals.